Effect of uric acid on mitochondrial function and oxidative stress in hepatocytes

Y. Yang¹, Y. Zhou², S. Cheng¹, J.L. Sun¹, H. Yao³ and L. Ma¹

¹School of Public Health, Xinjiang Medical University, Xinjiang, Urumqi, China
²School of Basic Medicine, Xinjiang Medical University, Xinjiang, Urumqi, China
³The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, Urumqi, China

Corresponding author: L. Ma
E-mail: maling3633@126.com

Received March 23, 2016
Accepted April 11, 2016
Published June 24, 2016
DOI http://dx.doi.org/10.4238/gmr.15028644

ABSTRACT. Here, we investigated the effect of uric acid (UA) on hepatocyte mitochondria. Hepatocytes cultured in vitro were treated with varying concentrations of UA. The change in apoptotic activity was detected by flow cytometry. The DNA damage index 8-hydroxy-deoxyguanosine (8-OHdG) and mitochondrial function indices succinate dehydrogenase (SDH), cytochrome C oxidase (CCO), and adenosine triphosphate (ATP) were detected by enzyme assays. Reactive oxygen species (ROS) accumulation was confirmed by a dichloro-dihydrofluorescein diacetate assay. We observed an increase in apoptotic activity, ROS accumulation, and 8-OHdG activity in hepatocytes treated with UA for extended periods, indicating DNA damage; specifically, we observed a significant increase in these activities 48, 72, and 96 h after UA addition, compared to those observed at 24 h (P < 0.05). Cells treated with 30 mg/dL UA for 96 h showed a peak in apoptotic activity. We also observed a significant decrease in ATP, SDH, and CCO activities with the increase in uric acid concentration over time.
Cells treated with 30 mg/dL UA for 96 h showed the highest ATP levels, while SDH and CCO activities at 48, 72, and 96 h post-UA treatment were significantly lower than those at 24 h (P < 0.01). Moreover, cells treated with 30 mg/dL UA showed a 0.02 ± 0.02 and 0.15 ± 0.01 μmol/mg/min decrease in SDH and CCO levels after 72 h. Therefore, we concluded that high concentrations of UA may induce oxidative stress in hepatocyte mitochondria, increasing ROS production and ultimately resulting in mitochondrial damage.

Key words: Uric acid; Mitochondrial damage; Oxidative stress; Cell apoptosis; DNA damage

INTRODUCTION

Human infants produce uric acid (UA), a major endogenous water-soluble antioxidant, as an end-product of purine metabolism. Previous studies have shown a close association between UA production and non-alcoholic fatty liver disease (Li et al., 2009; Sirota et al., 2013), liver cancer (Port et al., 2014), and other liver diseases. Hepatocytes are the primary sites of UA generation. Aberrant UA metabolism can cause hepatocyte injury by inducing oxidative stress. The mitochondria is the primary organelle involved in restoring oxygen molecules, and is an important source of reactive oxygen species (ROS) (Kuhlbrandt, 2015). Purine metabolism occurs predominantly in hepatocytes, which contain 500-1000 mitochondria; therefore, these cells play a major role in oxidative stress. A previous study reported that mitochondrial stimulation resulted in hepatocyte damage, which, in turn, caused oxidative stress in hyperuricemic rats (Lanaspa et al., 2012). Another study conducted in a UA-induced non-alcoholic fatty liver showed that uric acid induced ROS production in the mitochondria, which led to increased fat synthesis and triglyceride accumulation (Choi et al., 2014). However, the exact mechanism of the effect of UA on hepatocyte mitochondrial function remains unclear. In this study, we investigated the effect of UA on hepatocyte mitochondrial function and oxidative stress in vitro.

MATERIAL AND METHODS

Reagents and antibodies

Hepatocytes (L-02) were purchased from KeyGEN Biotech Development Co., Ltd. (Nanjing, China). Culture media (Dulbecco’s modified Eagle’s medium; DMEM), phosphate-buffered saline (PBS), and fetal bovine serum (FBS) were obtained from Gibco (Grand Island, NY, USA). Trypsin (2.5%) and double antibody were also purchased from Gibco. Uric acid powder was obtained from Sigma-Aldrich (St. Louis, MO, USA), while the Mitochondrial Extraction Kit was purchased from Beijing Solarbio Science and Technology (Beijing, China). Commercial kits for the detection of succinate dehydrogenase (SDH) and cytochrome C oxidase (CCO) were purchased from GenMed Medical Science and Technology (Shanghai, China). The human 8-hydroxy-deoxyguanosine (8-OHdG) ELISA kit was purchased from Bio-Swamp Immunoassay R&D Center (Guangzhou, China), while commercial kits for the measurement of ATP and ROS, and the BCA protein assay kit, were purchased from Nanjing.
Jiancheng Bioengineering Institute (Nanjing, China). Fluorescein isothiocyanate (FITC)-labeled Annexin V and propidium iodide were obtained from BD Biosciences (Franklin Lakes, NJ, USA).

**Cell culture and chemical treatment**

The hepatocytes were maintained in DMEM supplemented with 10% FBS in a 5% CO₂ incubator at 37°C (Wang et al., 2015). At a confluence rate of 80%, the cells were treated with different concentrations of UA (5, 10, 20, and 30 mg/dL) and cultured for 24, 48, 72, and 96 h. The control group was treated with 0 mg/dL UA. The cells were subsequently harvested and analyzed.

**Detection of apoptosis in hepatocytes by flow cytometry**

The apoptotic frequency in treated hepatocytes was measured by an Annexin V-FITC/propidium iodide double-staining method (Gao et al., 2015). Briefly, cells treated with UA for 24, 48, 72, and 96 h were collected and stained with binding buffer containing 10 µL propidium iodide and 5 µL Annexin V in the dark at room temperature for 15 min. The stained cells were then analyzed with a FACSort flow cytometer (BD Biosciences). The percentage of cells in each phase of the cell cycle was calculated using the ModFit software (Verity Software House, Topsham, ME, USA).

**Intracellular ROS analysis**

Cells in the logarithmic phase of growth were added to a 6-well plate at a density of 1 x 10⁵ cells/well. Hepatocytes at a confluence rate of ~70% were treated with varying concentrations of UA [untreated cells (0 mg/dL) were used as controls] for 24, 48, 72, and 96 h. The cells were then incubated with dichloro-dihydro-fluorescein diacetate at a final concentration of 40 µM for 40 min, rinsed with PBS, and observed under a fluorescence microscope (10X) (Cao et al., 2015). The fluorescence intensity was determined using the ImageJ image analysis software (NIH, Bethesda, MD, USA).

**Measurement of mitochondrial function**

The mitochondria of hepatocytes treated with varying concentrations of UA for 24, 48, 72, and 96 h were isolated and their SDH, CCO, and ATP activities were determined using their corresponding assay kits, according to the manufacturer protocols; 8-OHdG expression in the mitochondria was also determined using a commercial kit. Protein concentrations were determined using the BCA protein assay kit. The SDH and CCO activities were expressed as µM/mg protein/min, while the ATP and 8-OHdG activities were presented as U/mg protein and pg/mg protein, respectively.

**Statistical analysis**

The obtained data were statistically analyzed using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). Data are reported as means ± standard deviation of three independent experiments,
and were analyzed by one-way analysis of variance (ANOVA). The results were considered to be statistically significant at $P < 0.05$ and highly significant at $P < 0.01$.

RESULTS

Effect of UA on apoptosis in hepatocytes

First, we investigated UA-induced apoptosis in L-02 cells. We observed an increase in the apoptosis rate in hepatocytes with the increase in UA concentration and treatment time (Figure 1); that is, the highest apoptosis rate was observed in cells treated with 30 mg/dL UA for 96 h (Figure 2). Cells treated with 20 and 30 mg/dL UA for 24 h showed apoptosis rates of 5.10 and 6.50%, which were significantly higher than the rate shown by cells in the control group ($P < 0.01$). Similarly, cells treated with 5, 10, 20, and 30 mg/dL UA for 48, 72, and 96 h showed significant increase in apoptotic rates (4.93, 6.03, 6.50, and 7.13%; 9.07, 10.66, 14.73, and 20.77%; and 11.67, 15.00, 29.33, and 35.47%, respectively) ($P < 0.01$). We also observed a progressive increase in the apoptotic rates in cells treated with 5 and 10 mg/dL UA for 24, 48, 72, and 96 h ($P < 0.01$), while cells treated with 20 and 30 mg/dL UA for 72 and 96 h showed significantly higher apoptotic rates than those treated for 24 h ($P < 0.01$).

**Figure 1.** Cells treated with UA [0 (control), 5, 10, 20, and 30 mg/dL]. A, B, C, D. UA treatment for 24, 48, 72, and 96 h, respectively. The horizontal and vertical axes represent Annexin V and propidium iodide staining, respectively.
Uric acid modulates mitochondrial function in hepatocytes

Effect of UA on ROS activity in hepatocytes

Next, we investigated the possible effect of UA on ROS production in L-02 cells. The fluorescence microscopy images showed an increase in fluorescence (related to ROS activity) corresponding to the increase in UA concentrations and treatment time; consequently, cells treated with 30 mg/dL UA for 96 h showed the highest fluorescent signals (Figure 3). The mean fluorescence value determined using Image J showed a similar trend; ROS production increased with the increase in UA concentration and time, and peaked at 96 h in cells treated with 30 mg/dL (Figure 4).

Figure 3. Measurement of ROS. Representative fluorescence images (original magnification 10X) of ROS production in cells treated with different UA concentrations [0 (control), 5, 10, 20, and 30 mg/dL] and for different periods (24, 48, 72, and 96 h). A, B, C, D. UA treatment for 24, 48, 72, and 96 h, respectively. Cells producing ROS were stained green.
We observed a significant increase in the mean fluorescence value of ROS in cells treated with 20 and 30 mg/dL UA compared to those treated with 5 and 10 mg/dL UA for 24 h (P < 0.05). On the other hand, cells treated with 30 mg/dL UA for 72 h showed a significant increase in ROS production compared to those treated with 5, 10, and 20 mg/dL UA (P < 0.01). Cells treated with 30 mg/dL UA for 96 h also showed a significant increase in ROS production compared to those treated with 5, 10, and 20 mg/dL (P < 0.05). ROS levels were significantly higher in cells treated with 20 mg/dL UA for 72 and 96 h, compared to those treated with the same amount of UA for 24 and 48 h (P < 0.01). Additionally, ROS production increased progressively in cells treated with 10 mg/dL UA for 24, 48, 72, and 96 h (P < 0.01). On the other hand, cells treated with 20 mg/dL UA for 72 h showed significantly higher ROS levels than those treated for 24 h (P < 0.05), while cells treated for 96 h showed the highest increase compared to cells treated for shorter time periods (P < 0.01). Cells treated with 30 mg/dL UA for 96 h showed a maximum increase in ROS (0.024 pixels).

**Effect of uric acid on DNA damage in hepatocytes**

8-OHdG levels were measured to determine the possible effect of UA on oxidative DNA damage in L-02 cells. The cells were treated with varying concentrations of UA (0 = control, 5, 10, 20, and 30 mg/dL) for 24, 48, 72, and 96 h. As shown in Figure 5, we observed a significant increase in 8-OHdG levels with the increase in UA concentrations and treatment times. Specifically, cells treated with 30 mg/dL UA for 48, 72, and 96 h showed the most significant increase in 8-OHdG levels (P < 0.01). Cells treated with 20 and 30 mg/dL for 24 and 96 h showed a significant increase in 8-OHdG levels, compared to cells treated with 5 mg/dL UA (P < 0.01). We also observed a progressive and significant increase in 8-OHdG levels in cells treated with 5, 10, 20, and 30 mg/dL UA for 48 and 72 h (P < 0.01). At 96 h, the 8-OHdG levels in cells treated
with 20 and 30 mg/dL UA were 0.52 ± 0.21 and 1.03 ± 0.44 pg/mg, which were significantly increased compared to the level seen in cells treated with 5 mg/dL UA (0.24 ± 0.18 pg/mg) (P < 0.01). Additionally, cells treated with 5 mg/dL UA for 96 h showed significantly higher 8-OHdG levels compared to those treated for 24, 48, and 72 h (P < 0.01). On the other hand, 8-OHdG levels increased progressively in cells treated with 10 and 30 mg/dL UA for 24, 48, 72, and 96 h (P < 0.01 for all), while those treated with 20 mg/dL UA showed higher concentrations of 8-OHdG levels at 72 and 96 h compared to those at 24 and 48 h (P < 0.01). Cells treated with 30 mg/dL UA for 96 h showed the highest level of 8-OHdG (1.46 ± 0.03 pg/mg).

Figure 5. 8-OHdG content determined using the 8-OHdG ELISA kit. The cells were treated with different concentrations of UA [0 (control), 5, 10, 20, and 30 mg/dL] for 24, 48, 72, and 96 h. The results are representative of three independent experiments (means ± SD). The asterisk symbols denote significant differences between the ATP, SDH, and CCO levels in UA-treated groups and the control group: *P < 0.05 and **P < 0.01.

Effect of UA on mitochondrial function in hepatocytes

UA induced a decrease in the secretion of ATP, SDH, and CCO (Table 1) in hepatocytes. Cells treated with 10, 20, and 30 mg/dL UA for 24 h showed a highly significant decrease in ATP activity compared to those treated with 5 mg/dL UA for the same period of time (P < 0.01); treatment with 30 mg/dL UA induced a highly significant decrease in ATP compared to the 10- and 20-mg/dL UA treatment (P < 0.05). On the other hand, cells treated with 10, 20, and 30 mg/dL UA for 48 h showed a significant decrease in ATP levels compared to those treated with 5 mg/dL UA (P < 0.05); cells in the 30-mg/dL UA (48 h) group showed a significant decrease in ATP activity compared to those in the 10-mg/dL UA group (P < 0.05). Cells treated with 20 and 30 mg/dL UA for 72 h showed lower levels of ATP compared to those treated with 5 and 10 mg/dL UA (P < 0.01). This decrease was more significant in the 30-mg/dL UA group compared to that in the 20-mg/dL UA group (P < 0.05). At 96 h, we observed a decrease in ATP activities in all groups of cells, excluding the 20- and 30-mg/dL groups (P < 0.05). Therefore, we observed that UA treatment led to a significant decrease in ATP activity (P < 0.01). Cells treated with 5 mg/dL UA showed a significant decrease in ATP activity at all time.
points (P < 0.01), while those treated with 10 and 20 mg/dL UA for 48, 72, and 96 h showed a significant downregulation in ATP levels compared to the 24-h group (P < 0.01). We observed a significant decrease in ATP levels in cells treated for 96 h compared to that in cells treated for 48 and 72 h (P < 0.01). Cells treated with 30 mg/dL UA for 48, 72, and 96 h showed a significant decrease in ATP activity compared to those treated for 24 h (P < 0.01). Cells treated for 96 h with 30 mg/dL UA showed the least amount of ATP activity, at 0.05 ± 0.01 U/mg.

<table>
<thead>
<tr>
<th>Target</th>
<th>Time (h)</th>
<th>Control group</th>
<th>Uric acid level</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATP (U/mg)</td>
<td>24</td>
<td>1.10 ± 0.08</td>
<td>1.24 ± 0.02**</td>
</tr>
<tr>
<td></td>
<td>48</td>
<td>0.46 ± 0.42</td>
<td>0.64 ± 0.02</td>
</tr>
<tr>
<td></td>
<td>72</td>
<td>0.30 ± 0.02</td>
<td>0.35 ± 0.06</td>
</tr>
<tr>
<td></td>
<td>96</td>
<td>0.27 ± 0.04</td>
<td>0.27 ± 0.04</td>
</tr>
<tr>
<td>SDH (μmol/mg/min)</td>
<td>24</td>
<td>0.39 ± 0.02</td>
<td>0.58 ± 0.00**</td>
</tr>
<tr>
<td></td>
<td>48</td>
<td>0.21 ± 0.26</td>
<td>0.36 ± 0.24</td>
</tr>
<tr>
<td></td>
<td>72</td>
<td>0.13 ± 0.00</td>
<td>0.30 ± 0.02**</td>
</tr>
<tr>
<td></td>
<td>96</td>
<td>0.09 ± 0.01</td>
<td>0.09 ± 0.02</td>
</tr>
<tr>
<td>CCO (μmol/mg/min)</td>
<td>24</td>
<td>2.04 ± 0.33</td>
<td>1.67 ± 0.10</td>
</tr>
<tr>
<td></td>
<td>48</td>
<td>0.96 ± 0.32</td>
<td>0.59 ± 0.11</td>
</tr>
<tr>
<td></td>
<td>72</td>
<td>0.77 ± 0.40</td>
<td>0.31 ± 0.18</td>
</tr>
<tr>
<td></td>
<td>96</td>
<td>0.34 ± 0.17</td>
<td>0.27 ± 0.20</td>
</tr>
</tbody>
</table>

ATP, SDH, and CCO levels were assessed using commercial kits. The cells were treated with UA [0 (control], 5, 10, 20, and 30 mg/dL) for 24, 48, 72, and 96 h. Results are representative of three independent experiments (means ± SD). The asterisk symbols denote significant differences between the ATP, SDH, and CCO levels in UA-treated groups and the control group: *P < 0.05 and **P < 0.01.

We observed a significant decrease in SDH activity in cells treated with 20 and 30 mg/dL UA for 24 h compared to those treated with 5 and 10 mg/dL UA (P < 0.01). Cells treated with 30 mg/dL for 48 h showed a considerable decrease in SDH activity compared to those treated with 5 mg/dL for the same period of time (P < 0.05). At 72 h, all UA groups excluding the 10- and 20-mg/dL UA groups displayed a significant decrease in SDH activity (P < 0.05). Similarly, at 96 h, we observed a significant decrease in SDH levels in cells treated with 20 and 30 mg/dL UA compared to those treated with 5 and 10 mg/dL UA (P < 0.05). Cells treated with 5 mg/dL for 72 and 96 h showed a significant decrease in SDH levels compared to the 24 h treatment group (P < 0.05); moreover, the 96-h group showed lower SDH activity than the 48- and 72-h treatment groups (P < 0.05). Cells treated with 10 mg/dL UA of 48 h showed a significant decrease in SDH compared to those treated for 24 h (P < 0.05); additionally, UA treatment for 72 and 96 h induced a significant decrease in SDH compared to treatment for 24 and 48 h (P < 0.01). Cells treated with 20 mg/dL UA for 48, 72, and 96 h showed a significant decrease in SDH activity compared to those treated for 24 h (P < 0.01). Moreover, the 72- and 96-h treatment groups showed a significant decrease in SDH levels compared to the 48-h treatment group (P < 0.01). Cells treated with 30 mg/dL UA for 48, 72, and 96 h showed a significant decrease in SDH compared to those treated for 24 h (P < 0.01). Finally, cells treated with 30 mg/dL UA for 72 h showed the lowest amount of SDH (0.02 ± 0.02 μmol/mg/min).

Cells treated with 30 mg/dL UA for 72 h showed a significant decrease in CCO compared to those treated with 5 mg/dL UA (P < 0.01). Cells treated with 5 mg/dL UA for 48, 72, and 96 h also showed a significant decrease in CCO compared to those treated for 24 h (P < 0.01); treatment for 96 and 72 h induced a highly significant decrease, compared to the 48-h treatment (P < 0.05). Cells treated with 10 mg/dL UA for 48, 72, and 96 h also showed a significant decrease in CCO compared to those treated for 24 h (P < 0.01). Cells treated with 30 mg/dL UA for 72 h showed the lowest CCO activity (0.15 ± 0.01 μmol/mg/min).
DISCUSSION

Data obtained from experimental and clinical studies indicated that UA plays a dual role as an anti-oxidant (Glantzounis et al., 2005) and pro-oxidant (Zhang et al., 2015) in hepatocytes. Previous studies have shown that UA exerts a detrimental effect as a pro-oxidant in cultured cells and in an animal model of hyperuricemia (Sautin et al., 2007; Kang and Ha, 2014). Preliminary experiments, wherein the cell viability was detected using an MTT assay, indicated that hepatocyte viability increased with the increase in UA concentration over time; this showed that UA does not suppress the growth and propagation of hepatocytes, and does not induce cell necrosis. However, microscopic analyses revealed that high concentrations of UA (20 and 30 mg/dL) induced a change in cell morphology, although the number of cells remained unaffected. The morphological changes included shrinking of cells, loss of glossy surface, and a darker color. Moreover, we observed an increase in glutamic oxaloacetic transaminase and glutamic pyruvic transaminase expression in cells treated with increasing UA concentrations over extended periods of time. These results suggest that high levels of UA may induce functional damage in hepatocytes (Yang et al., 2015).

Our results suggested that hepatocytes treated with high concentrations of UA for extended periods displayed an increase in apoptosis, as well as 8-OHdG and ROS activities. ROS are continuously generated during respiration. Under normal conditions, ROS production and clearance occurs in dynamic equilibrium; however, factors such as stress induce an oxidant-antioxidant imbalance, which leads to the production and accumulation of large amounts of ROS. Slow ROS clearance promotes oxidative stress-induced oxidative damage to biological macromolecules, cellular structures, and DNA (Avery, 2011). In this study, the increase in ROS levels corresponded to the increase in UA levels over time, indicating that UA enhanced oxidative stress in hepatocytes. The results of this study indicated that the presence of UA at concentrations greater than physiological levels induces apoptosis, a form of programmed cell death, in hepatocytes. These results are similar to those obtained by Yu et al. (2010), who reported that UA promotes apoptosis in human umbilical vein endothelial cells. Previous studies have shown that ROS enhances apoptosis by inducing oxidative stress during neuronal injury (Loh et al., 2006). Another study proposed that apoptotic events occurring under high UA levels are dependent on ROS generation (Verzola et al., 2014). Moreover, another study reported that mitochondrial dysfunction results in the loss of CCO, inducing an increase in ROS expression and subsequently triggering the intrinsic apoptotic cascade protein (Circu and Aw, 2010), which is similar to the results of our experiment. Therefore, we concluded that increased apoptosis in hepatocytes may be due to UA-induced accumulation of ROS, resulting in increased oxidative stress in hepatocytes. 8-OHdG is a product of highly mutagenic DNA oxidative damage; moreover, it is widely expressed in the nucleus, mitochondria, and metabolites in eukaryotic cells, and prokaryotic cells. Therefore, it can be used as a marker for the detection of DNA damage (Martin, 2008). In this study, we observed an increase in 8-OHdG expression in hepatocytes treated with increasing levels of UA for greater periods, indicating that UA enhances DNA damage in hepatocytes. Avery (2011) reported that ROS causes DNA damage by inducing oxidative stress via lipid peroxidation. Another study reported that ROS causes oxidative damage to DNA (Oka et al., 2008). Therefore, the increase in 8-OHdG content in the hepatocytes could be attributed to the promotion of DNA oxidative damage by UA-induced ROS.

Our results suggest that the presence of UA can decrease ATP, SDH, and CCO activities...
in the mitochondria of hepatocytes. Mitochondria are the main sites of ATP generation (Kuhlbrandt, 2015). High levels of UA were previously found to induce mitochondrial dysfunction, which may lead to excess ROS generation. This suggested that mitochondrial uncoupling decreases the synthesis of ATP via oxidative phosphorylation (Sánchez-Lozada et al., 2012). Therefore, we hypothesized that the decrease in ATP content in the hepatocyte mitochondria was correlated with mitochondrial uncoupling promoted by UA-induced ROS. SDH maintains the function of the electron transport chain and tricarboxylic acid cycle in the mitochondria. To a certain extent, its vitality reflects the integrity of the mitochondrial membrane and explains the role of the Krebs cycle in energy metabolism. The results of our study suggested that high levels of UA in hepatocytes significantly reduced the SDH activity in the mitochondria, indicating that UA damages the mitochondrial membrane structure and inhibits mitochondrial energy metabolism. CCO is an essential enzyme that produces a proton gradient for ATP production during mitochondrial oxidative phosphorylation (Yoshikawa et al., 2015). The results of our study suggest that high levels of UA in hepatocytes significantly reduced CCO activity in the mitochondria. A previous study showed that mitochondrial ATP production can be upregulated via positive regulation of CCO activity, thereby preventing myocardial cell hypoxia (Hayashi et al., 2015), while another study showed that lower CCO vitality can lead to an increase in ROS generation in the mitochondria (Srinivasan and Avadhani, 2012); these studies support our conclusion that UA-induced oxidative stress in liver mitochondria, and alterations to mitochondrial function, result in cell damage.

CONCLUSIONS

Overall, our results suggest that UA induces oxidative stress response in the mitochondria, exacerbating mitochondrial dysfunction. This decreases CCO and SDH expression and reduces ATP production. Reduced secretion of CCO further decreases the ability of mitochondria to generate superoxide, leading to increased production and accumulation of ROS, ultimately promoting hepatocyte apoptosis, mitochondrial dysfunction, and DNA damage.

Conflicts of interest

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

Research partially supported by the Natural Science Foundation of the Xinjiang Uygur Autonomous Region, China (#2015211C011 to L. Ma).

REFERENCES

Choi YJ, Shin HS, Choi HS, Park JW, et al. (2014). Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab. Invest. 94: 1114-1125. [http://dx.doi.org/10.1038/labinvest.2014.98](http://dx.doi.org/10.1038/labinvest.2014.98)
Uric acid modulates mitochondrial function in hepatocytes


